Leading independent European antisense drug discovery company, Secarna, aims to bring novel and effective antisense therapeutic options to an increasing number of patients. CEO Alexander Gebauer tells us how.
Research conducted by the University of Surrey suggests that insulin icodec, a weekly basal injection, may be just as effective when treating type 1 diabetes compared to daily basal insulin treatments.
Poor adherence to drug therapies can lead to medication waste and poor patient outcomes. Tim Wooller shares some of the reasons behind poor adherence to medication and how connected drug delivery devices can help.
The National Institutes of Health and Salk Institute researchers have made strides in understanding the molecular mechanisms behind HIV drug resistance mechanisms.
Simone Schoenwaelder from Australia’s Heart Research Institute tells us about exciting advancements in stroke research and care that could dramatically improve clinical outcomes for patients.
An experimental Alzheimer's drug called donanemab, developed by Eli Lilly, has demonstrated a slowdown in progression of disease at early stages, according to trial data.
Cosmo Feilding-Mellen, CEO, Beckley Psytech, charts the role of psychedelics in mitigating Treatment Resistant Depression
This post has been moved. Please continue reading here.
https://www.openaccessgovernment.org/article/psychedelics-mitigate-treatment-resistant-depression/163713/
A groundbreaking study demonstrates the efficacy of administering a previously injection-only medication for osteoporosis through an innovative robotic pill.
AI and Anti-aging research: According to a study, AI algorithms (AI) has led to the discovery of three drugs that have the potential to delay the effects of aging.
Monica Racoviță, Senior Researcher at The Health Policy Partnership, argues that opioid dependence is a pressing issue, yet treatment for it is still out of reach for many.
